Navigation Links
iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection (HCV).  ITX-5061 represents a first-in-class compound that inhibits entry of the hepatitis C virus into liver cells.

"ITX-5061 possesses a unique mechanism of action that prevents the hepatitis C virus from entering liver cells and has demonstrated potent preclinical antiviral activity against all HCV genotypes.In addition, it has already demonstrated safety in more than 280 subjects," said Jeffrey McKelvy, PhD, MD, President and Chief Executive Officer of iTherX.  "We hope ITX-5061 will significantly improve long-term transplant outcomes."

The primary objective of the Phase 1b clinical trial will be to assess the safety and tolerability of ITX-5061 in liver transplant patients.  The study will also assess HCV viral load for three months after liver transplantation to determine if ITX-5061 has any immediate and/or sustained impact on viral kinetics in treated patients. Approximately 20 patients will be enrolled into one of two cohorts:  one group will receive supportive care only, while the second cohort will also receive ITX-5061 at a150 mg daily dose for seven days.  The trial is being conducted at the University of Birmingham, UK under the direction of David Mutimer, MBBS, MD, FRACP, FRCP, Reader in Hepatology at Birmingham University and Consultant Hepatologist to the Birmingham QE Hospital Liver and Hepatobiliary Unit.

Preclinical studies have shown ITX-5061 to be a potent and selective inhibitor of HCV entry into hepatocytes, capable of preventing virus binding/fusion and cell to cell spread, suggesting ITX-5061  may reduce re-infection rates followi
'/>"/>

SOURCE iTherX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
2. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
3. New Mexico Software Initiates Medical Second Opinion Service via Telemedicine for Remote Consultation Review
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigalâ„¢ Co-administered with Enzyme Replacement Therapy
6. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
7. American Regent Initiates Nationwide Voluntary Recall of Sodium Thiosulfate Injection, USP
8. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
9. Zacks Investment Research Initiates Coverage on Viral Genetics
10. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... Mass. , Sept. 12, 2014  Royal Philips ... a number of innovations at ASTRO,s 56th Annual ... showcasing solutions that increase workflow automation, confidence, consistency and ... time and enhancing patient-centric care, these radiation oncology solutions ... of a more personalized approach to medicine. ...
(Date:9/12/2014)... -- WellStar Paulding Hospital is the first hospital in ... the U.S. to offer a new, innovative procedure to ... Paulding Hospital is on the cutting edge of medical ... Inspire Therapy offers relief for moderate to severe ... use traditional treatments, like Continuous Positive Airway Pressure (CPAP). ...
(Date:9/12/2014)... September 12, 2014 According to ... (Glucose Monitoring & Infectious Diseases Testing Kits, Cardiac & ... Over the Counter & Prescription Based - Global Forecast ... POC Diagnostics Market over the forecast period of 2013 ... a CAGR of 9.3% from 2013 to 2018, to ...
Breaking Medicine Technology:Philips Demonstrates Commitment to Radiation Oncology Solutions at ASTRO 2014 2Philips Demonstrates Commitment to Radiation Oncology Solutions at ASTRO 2014 3WellStar Pioneers New Sleep Apnea Treatment 2Point-Of-Care Diagnostic Market Worth $27.5 Billion by 2018 2Point-Of-Care Diagnostic Market Worth $27.5 Billion by 2018 3Point-Of-Care Diagnostic Market Worth $27.5 Billion by 2018 4
... Neb., May 15 Creighton Medical Laboratories, based at ... announced today that it has become the first clinical ... testing method for cancer. The method, called SNP array ... to study cancer for several years. However, Creighton Medical ...
... Case Demonstrating RenalGuard To Be PresentedFRANKLIN, Mass., May ... PLCSF), a company focused on innovative cardiac and ... will demonstrate its RenalGuard System(TM) at EuroPCR, the ... Cardiovascular Interventions (EAPCI), May 19-22, 2009, in Barcelona, ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 2PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 4
(Date:9/15/2014)... (PRWEB) September 15, 2014 (PRWEB) September 15, 2014 ... not; what the startup business requirements are in each ... new business. , Speakers include industry professionals, such as ... Center in Oakland,CA and cannabis business consultant ... who are already successfully running legal marijuana businesses all ...
(Date:9/15/2014)... Concox , a leading designer and manufacturer of ... to bringing reliable products and customized solutions to clients ... products, GT06N not only looks appealing but has many ... and original GPS car and truck tracker with an ... on cars or trucks. , Concox has already introduced ...
(Date:9/14/2014)... St. Louis, MO (PRWEB) September 14, 2014 ... events can now use the Quotes Pros website to ... portal that was constructed this year at http://quotespros.com/life-insurance.html ... , The insurance company partners that are preparing ... this year are located in most U.S. states. As ...
(Date:9/14/2014)... 14, 2014 Proper oral care requires ... Butte, Mont., found a way to teach children to ... B LITE toothbrush encourages an effective brushing habit by ... two minutes without overbrushing, eliminating guesswork and promoting independence ... to use, suitable for all children, and producible in ...
(Date:9/14/2014)... Getting enough sleep each night may mean you,re less likely to ... suggests. The study included more than 3,700 people in Finland, ... seven years. Those who slept less than six hours or ... have extended absences from work due to illness, the investigators found. ... due to sickness were those who slept between seven and eight ...
Breaking Medicine News(10 mins):Health News:How to Start And Run a Successful Legal Marijuana Business 2Health News:iConcox GPS Vehicle Tracker GT06N Designed for Customers' Security 2Health News:Quotes for Life Insurance Now Offered at New Consumer Portal Online 2Health News:A Good Night's Sleep May Mean a Good Day's Work 2
... , , FRANKLIN ... (NYSE: MHS ), the world,s most advanced pharmacy(R) ... into a joint venture with United Drug plc, a Pan-European healthcare ... for patients covered by the country,s National Health Service (NHS). ...
... , MARINA DEL RAY, Calif., Aug. 12 Dr. ... to welcome Italian students from the University of L,Aquila by assisting ... school is being rebuilt after the devastating April 5th earthquake in ... who were displaced by the earthquake in L,Aquila, Italy, including the ...
... ISELIN, N.J., Aug. 12 Pharmos Corporation (Pink Sheets: PARS) today reported financial ... , Second Quarter Ended June 30, 2009 , ... or $0.05 per share, for the second quarter 2009 compared to a net ... Cash and cash equivalents totaled $2.9 million at June 30, 2009. , ...
... have given for years , WEDNESDAY, Aug. 12 (HealthDay News) ... painful swelling of the arm that often occurs after breast ... to what women have been told for years -- that ... other exercise because muscle strain can cause lymphedema to worsen. ...
... Goal is to help patients who might benefit from ... By clarifying rules governing patient access to so-called investigational ... to expand the number of people who might benefit ... can get the drugs hasn,t changed, but there is ...
... , WASHINGTON, Aug. 12 During a town ... stated his opposition to legislation that would cover illegal aliens. Specter ... was the author of the 2006 amnesty bill (S. 2611) that ... illegal aliens under the proposed reforms is a clear indication of ...
Cached Medicine News:Health News:Medco Health Solutions, United Drug Announce U.K. Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions; Innovations to Improve Clinical Quality, Reduce Costs 2Health News:Medco Health Solutions, United Drug Announce U.K. Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions; Innovations to Improve Clinical Quality, Reduce Costs 3Health News:Heritage Provider Network and Dr. Richard Merkin Come to the Aid of Italian Earthquake Victims 2Health News:Heritage Provider Network and Dr. Richard Merkin Come to the Aid of Italian Earthquake Victims 3Health News:Pharmos Corporation Reports 2009 Second Quarter Results 2Health News:Pharmos Corporation Reports 2009 Second Quarter Results 3Health News:Pharmos Corporation Reports 2009 Second Quarter Results 4Health News:Pharmos Corporation Reports 2009 Second Quarter Results 5Health News:Pharmos Corporation Reports 2009 Second Quarter Results 6Health News:Pharmos Corporation Reports 2009 Second Quarter Results 7Health News:Pharmos Corporation Reports 2009 Second Quarter Results 8Health News:Pharmos Corporation Reports 2009 Second Quarter Results 9Health News:Weight Lifting Can Ease Arm Swelling in Breast Cancer Survivors 2Health News:Weight Lifting Can Ease Arm Swelling in Breast Cancer Survivors 3Health News:FDA Details Access to 'Investigational' Drugs 2Health News:FDA Details Access to 'Investigational' Drugs 3Health News:Specter Promises to Oppose Health Care Reform That Covers Illegal Aliens 2
... Detect™ IgM Capture ELISA is for the ... WNV recombinant antigens (WNRA) in serum as ... of West Nile virus infection in patients ... results must be confirmed by Plaque Reduction ...
Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: